{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:48Z","timestamp":1792783428918,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K19553"],"award-info":[{"award-number":["JP25K19553"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03100"],"award-info":[{"award-number":["22H03100"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24nk0101XXXh0X0X"],"award-info":[{"award-number":["24nk0101XXXh0X0X"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Tokyo","id":[{"id":"https:\/\/ror.org\/057zh3y96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy has revolutionized cancer treatments, yet checkpoint inhibitors and CAR-T cells have shown limited efficacy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This limited efficacy is primarily due to the absence of lineage-specific antigens and the presence of suppressive microenvironments. Innate immunity offers a promising alternative, as it acts independently of neoantigens. The key players such as macrophages, dendritic cells, and natural killer (NK) cells not only eliminate malignant cells but also remodel the microenvironment to enhance antileukemic activity. This review highlights recent advances in understanding innate immune mechanisms in AML and MDS and explores therapeutic strategies designed to leverage these pathways, aiming to broaden the scope of immunotherapy.<\/jats:p>","DOI":"10.1007\/s12185-025-04113-x","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:18:12Z","timestamp":1763731092000},"page":"478-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent advances of cell therapies for AML\/MDS: exploring the therapeutic potential of innate immune cells in AML\/MDS"],"prefix":"10.1007","volume":"124","author":[{"given":"Yu-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-1826","authenticated-orcid":false,"given":"Susumu","family":"Goyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"4113_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"4113_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3324\/haematol.2014.118679","volume":"100","author":"M Hejazi","year":"2015","unstructured":"Hejazi M, Manser AR, Frobel J, Kundgen A, Zhao X, Schonberg K, et al. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 2015;100:643\u201352.","journal-title":"Haematologica"},{"key":"4113_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3324\/haematol.2013.087536","volume":"99","author":"K Stringaris","year":"2014","unstructured":"Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99:836\u201347.","journal-title":"Haematologica"},{"key":"4113_CR4","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","volume":"195","author":"Z Khaznadar","year":"2015","unstructured":"Khaznadar Z, Boissel N, Agaugu\u00e9 S, Henry G, Cheok M, Vignon M, et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol. 2015;195:2580\u201390.","journal-title":"J Immunol"},{"key":"4113_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572:254\u20139.","journal-title":"Nature"},{"key":"4113_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","volume":"22","author":"I Gon\u00e7alves Silva","year":"2017","unstructured":"Gon\u00e7alves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, et al. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44\u201357.","journal-title":"EBioMedicine"},{"key":"4113_CR7","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","volume":"115","author":"T Baessler","year":"2010","unstructured":"Baessler T, Charton JE, Schmiedel BJ, Gr\u00fcnebach F, Krusch M, Wacker A, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood. 2010;115:3058\u201369.","journal-title":"Blood"},{"key":"4113_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989\u20131004.","journal-title":"Immunity"},{"issue":"5562","key":"4113_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100. https:\/\/doi.org\/10.1126\/science.1068440.","journal-title":"Science"},{"key":"4113_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","volume":"131","author":"J Cany","year":"2018","unstructured":"Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R, et al. Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD\/SCID\/IL2Rgnull mice. Blood. 2018;131:202\u201314.","journal-title":"Blood"},{"key":"4113_CR11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s42003-023-05606-3","volume":"6","author":"E Sugimoto","year":"2023","unstructured":"Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, et al. Hyperactive natural killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia. Commun Biol. 2023;6:1294.","journal-title":"Commun Biol"},{"key":"4113_CR12","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41467-019-12555-1","volume":"10","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, et al. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nat Commun. 2019;10:4869.","journal-title":"Nat Commun"},{"issue":"8","key":"4113_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114536","volume":"43","author":"Y-H Chang","year":"2024","unstructured":"Chang Y-H, Yamamoto K, Fujino T, Wang T-W, Sugimoto E, Zhang W, et al. SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Cell Rep. 2024;43(8):114536. https:\/\/doi.org\/10.1016\/j.celrep.2024.114536.","journal-title":"Cell Rep"},{"key":"4113_CR14","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439.","journal-title":"Nat Commun"},{"key":"4113_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell. 2020;27:224-237.e6.","journal-title":"Cell Stem Cell"},{"key":"4113_CR16","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"J-I Youn","year":"2008","unstructured":"Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791\u2013802.","journal-title":"J Immunol"},{"key":"4113_CR17","doi-asserted-by":"publisher","first-page":"16554","DOI":"10.1038\/s41598-020-73624-w","volume":"10","author":"M Oshi","year":"2020","unstructured":"Oshi M, Tokumaru Y, Asaoka M, Yan L, Satyananda V, Matsuyama R, et al. M1 macrophage and M1\/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci Rep. 2020;10:16554.","journal-title":"Sci Rep"},{"key":"4113_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2023-178589","volume":"142","author":"G Qiu","year":"2023","unstructured":"Qiu G, Xu X, Xue H, Zhang T, Xuan L, Liu Q. CD74 + leukemia-associated macrophages suppress t cell immune surveillance and promote leukemic cell growth in acute myeloid leukemia. Blood. 2023;142:289\u2013289.","journal-title":"Blood"},{"key":"4113_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","volume":"44","author":"V Kumar","year":"2016","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 2016;44:303\u201315.","journal-title":"Immunity"},{"key":"4113_CR20","doi-asserted-by":"publisher","first-page":"eadf8522","DOI":"10.1126\/sciadv.adf8522","volume":"9","author":"I Weinh\u00e4user","year":"2023","unstructured":"Weinh\u00e4user I, Pereira-Martins DA, Almeida LY, Hilberink JR, Silveira DRA, Quek L, et al. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism. Sci Adv. 2023;9:eadf8522.","journal-title":"Sci Adv"},{"key":"4113_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"4113_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","volume":"38","author":"A Perzolli","year":"2024","unstructured":"Perzolli A, Koedijk JB, Zwaan CM, Heidenreich O. Targeting the innate immune system in pediatric and adult AML. Leukemia. 2024;38:1191\u2013201.","journal-title":"Leukemia"},{"key":"4113_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432\u201347.","journal-title":"Cell Mol Immunol"},{"key":"4113_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1419114","author":"JL Hsu","year":"2018","unstructured":"Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana D, et al. A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. Oncoimmunology. 2018. https:\/\/doi.org\/10.1080\/2162402X.2017.1419114.","journal-title":"Oncoimmunology"},{"issue":"2","key":"4113_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020165","volume":"12","author":"F Palomares","year":"2024","unstructured":"Palomares F, Pina A, Dakhaoui H, Leiva-Castro C, Munera-Rodriguez AM, Cejudo-Guillen M, et al. Dendritic cells as a therapeutic strategy in acute myeloid leukemia: vaccines. Vaccines. 2024;12(2):165. https:\/\/doi.org\/10.3390\/vaccines12020165.","journal-title":"Vaccines"},{"key":"4113_CR26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028199","author":"P Goel","year":"2025","unstructured":"Goel P, Aryal S, Franceski AM, Kuznetsova V, Costa AFDO, Luca F, et al. The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF\u03baB signaling. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024028199.","journal-title":"Blood"},{"key":"4113_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568875","author":"LC Bento","year":"2025","unstructured":"Bento LC, Cebinelli GM, Bacal NS, Marti LC. Innate lymphoid cells in bone marrow and peripheral blood of healthy individuals and in bone marrow of patients with myelodysplastic syndromes. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1568875.","journal-title":"Front Immunol"},{"key":"4113_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","volume":"8","author":"S Trabanelli","year":"2017","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salom\u00e9 B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8:593.","journal-title":"Nat Commun"},{"key":"4113_CR29","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41375-020-0843-8","volume":"34","author":"L Wu","year":"2020","unstructured":"Wu L, Lin Q, Ma Z, Chowdhury FA, Mazumder MHH, Du W. Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia. 2020;34:3028\u201341.","journal-title":"Leukemia"},{"key":"4113_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","volume":"3","author":"RM McEwen-Smith","year":"2015","unstructured":"McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015;3:425\u201335.","journal-title":"Cancer Immunol Res"},{"key":"4113_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00262-022-03268-4","volume":"72","author":"V Stavrou","year":"2023","unstructured":"Stavrou V, Fultang L, Booth S, De Simone D, Bartnik A, Scarpa U, et al. Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment. Cancer Immunol Immunother. 2023;72:543\u201360.","journal-title":"Cancer Immunol Immunother"},{"key":"4113_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1182\/blood-2024-199471","volume":"144","author":"S Forst\u00e9n","year":"2024","unstructured":"Forst\u00e9n S, Penter L, Br\u00fcck OE, Smolander J, Peltonen K, L\u00e4hdesm\u00e4ki H, et al. Comparison of anti-PD1, anti-CTLA4 and anti-TIM3 in treatment of AML patients with single-cell transcriptomics displays different effects on immune subtypes. Blood. 2024;144:1529\u20131529.","journal-title":"Blood"},{"issue":"11","key":"4113_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101826","volume":"5","author":"V Rubino","year":"2024","unstructured":"Rubino V, H\u00fcppi M, H\u00f6pner S, Tortola L, Schn\u00fcriger N, Legenne H, et al. IL-21\/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T\u00a0cell therapy. Cell Rep Med. 2024;5(11):101826. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101826.","journal-title":"Cell Rep Med"},{"issue":"11","key":"4113_CR34","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","volume":"8","author":"S Guo","year":"2024","unstructured":"Guo S, Lei W, Jin X, Liu H, Wang JQ, Deng W, et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv. 2024;8(11):2635\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2023012202.","journal-title":"Blood Adv"},{"key":"4113_CR35","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011;121:4746\u201357.","journal-title":"J Clin Invest"},{"key":"4113_CR36","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.leu.2401872","volume":"14","author":"L Pan","year":"2000","unstructured":"Pan L, Ohnishi K, Zhang W, Yoshida H, Maksumova L, Muratkhodjaev F, et al. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression. Leukemia. 2000;14:1634\u201341.","journal-title":"Leukemia"},{"issue":"12","key":"4113_CR37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","volume":"2","author":"D Sarhan","year":"2018","unstructured":"Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Adv. 2018;2(12):1459\u201369. https:\/\/doi.org\/10.1182\/bloodadvances.2017012369.","journal-title":"Blood Adv"},{"key":"4113_CR38","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123:3016\u201326.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4113_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-136398","volume":"136","author":"ED Warlick","year":"2020","unstructured":"Warlick ED, Weisdorf DJ, Vallera DA, Wangen R, Lewis D, Knox J, et al. GTB-3550 TriKE\u2122 for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory\/relapsed acute myeloid leukemia (AML) safely drives natural killer (NK) cell proliferation at initial dose cohorts. Blood. 2020;136(Supplement 1):7\u20138. https:\/\/doi.org\/10.1182\/blood-2020-136398.","journal-title":"Blood"},{"key":"4113_CR40","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-025-63069-y","volume":"16","author":"N Schmitt","year":"2025","unstructured":"Schmitt N, Siegler J-J, Beck A, M\u00fcller T, Kozlowska I, Sarlang S, et al. The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nat Commun. 2025;16:7793.","journal-title":"Nat Commun"},{"key":"4113_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115718","volume":"168","author":"M Bakhtiyaridovvombaygi","year":"2023","unstructured":"Bakhtiyaridovvombaygi M, Yazdanparast S, Mikanik F, Izadpanah A, Parkhideh S, Shahbaz ghasabeh A, et al. Cytokine\u2010induced memory\u2010like NK cells: emerging strategy for AML immunotherapy. Biomed Pharmacother. 2023;168:115718.","journal-title":"Biomed Pharmacother"},{"key":"4113_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C. Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med. 2025;25:41.","journal-title":"Clin Exp Med"},{"key":"4113_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-025-00639-2","volume":"14","author":"B He","year":"2025","unstructured":"He B, Chen H, Wu J, Qiu S, Mai Q, Zeng Q, et al. Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways. Exp Hematol Oncol. 2025;14:51.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"4113_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9(12):e003894. https:\/\/doi.org\/10.1136\/jitc-2021-003894.","journal-title":"J Immunother Cancer"},{"key":"4113_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146:601\u201311.","journal-title":"Blood"},{"key":"4113_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.V126.23.1348.1348","volume":"126","author":"RO Jacamo","year":"2015","unstructured":"Jacamo RO, Mu H, Zhang Q, Chachad D, Zhiqiang W, Ma W, et al. Effects of CCL2\/CCR2 blockade in acute myeloid leukemia. Blood. 2015;126:1348\u20131348.","journal-title":"Blood"},{"key":"4113_CR47","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/blood-2018-03-838946","volume":"133","author":"DK Edwards","year":"2019","unstructured":"Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2019;133:588\u201399.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s12185-025-04153-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04113-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:26Z","timestamp":1791194366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04113-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04113-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to amend a typo in figure 1.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-025-04153-3","URL":"https:\/\/doi.org\/10.1007\/s12185-025-04153-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y-HC and SG declare no competing financial interests with the contents of this article. SG is an editor of International Journal of Hematology.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}